Innovate Biopharmaceuticals Schedules Conference Call to Provide Corporate and Operational Progress Updates
February 26, 2019 09:00 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
February 25, 2019 09:30 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer
February 22, 2019 10:00 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...
Innovate Biopharmaceuticals Announces Presentation at BIO CEO & Investor Conference
February 07, 2019 08:34 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) a clinical stage biotechnology company focused on developing novel autoimmune and inflammation...
Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019
December 17, 2018 08:00 ET
|
Innovate Biopharmaceuticals, Inc
Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro ...
Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018
December 04, 2018 11:15 ET
|
Innovate Biopharmaceuticals, Inc
-- Announces collaboration in high unmet need Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis, with novel gut-specific, clinical-stage asset, larazotide acetate-- Investor update...
Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.
November 26, 2018 06:00 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and...
Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights
November 13, 2018 17:26 ET
|
Innovate Biopharmaceuticals, Inc
Poster presentation at the American Association of Study of Liver Diseases showing promising pre-clinical data of larazotide acetate in NASH reducing intestinal permeability. Innovate plans to...
Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary “Leaky Gut” Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study
November 12, 2018 08:10 ET
|
Innovate Biopharmaceuticals, Inc
Significant effect on gut epithelial integrity, a mechanism thought to be key for bacterial translocation leading to NAFLD and NASH. Innovate plans to launch a clinical development program for NASH in...
Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference
November 05, 2018 09:15 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Innovate) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...